DDrare: Database of Drug Development for Rare Diseases

Fibrogammin®p, coagulation factor xiii concentrate (human) (DrugBank: Factor XIII)

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02551042 (ClinicalTrials.gov)	September 2015	17/12/2014	CSL Behring Sclero XIII	A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis	Systemic Sclerosis	Drug: Fibrogammin®P, coagulation factor XIII concentrate (Human);Drug: 0.9% sodium chloride	University College, London	CSL Behring	Recruiting	18 Years	N/A	Both	26	Phase 2	United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02551042
(ClinicalTrials.gov)

September 2015

17/12/2014

CSL Behring Sclero XIII

A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis

Systemic Sclerosis

Drug: Fibrogammin®P, coagulation factor XIII concentrate (Human);Drug: 0.9% sodium chloride

University College, London

CSL Behring

Recruiting

18 Years

N/A

Both

Phase 2

United Kingdom